IRAK4 Inhibitor Salts and Solid Forms for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and fibrotic disorders, such as rheumatoid arthritis and inflammatory bowel disease, often have limitations in efficacy and specificity, particularly in targeting the IRAK4 kinase pathway.
Innovation Solution
Development of salts and solid forms of a compound, specifically crystalline forms of Compound I and its salts, which act as inhibitors of IRAK4, offering potential therapeutic benefits for various inflammatory and fibrotic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and fibrotic disorders are used, then they can address some symptoms, but they have limitations in efficacy and specificity in targeting the IRAK4 kinase pathway
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Compound I to create different salts and solid forms (polymorphs, solvates, hydrates). These structural modifications change the physical and chemical parameters of the compound while maintaining its biological activity as an IRAK4 inhibitor, thereby improving both efficacy and specificity for treating inflammatory and fibrotic disorders
Solution Approach 2:
The patent employs local quality by creating specific crystalline forms with distinct X-ray powder diffractogram characteristics. Each crystal form has unique local molecular arrangements and properties that can enhance the compound's stability, solubility, or bioavailability, thereby improving therapeutic efficacy while maintaining specific IRAK4 inhibition
2Adaptability or versatility
If multiple solid forms and salts of Compound I are developed, then therapeutic options are expanded, but the complexity of the patent increases
Solution Approach 1:
The patent applies universality by demonstrating that multiple salts and solid forms of Compound I (including polymorphs, solvates, and hydrates) all function as IRAK4 inhibitors. This multi-functionality approach allows a single compound framework to provide multiple therapeutic options with potentially different pharmacokinetic properties, expanding treatment possibilities without requiring entirely different molecular structures
Solution Approach 2:
The patent uses segmentation by categorizing and characterizing different solid forms through systematic X-ray powder diffractogram analysis. By dividing the compound into distinct crystalline forms with identifiable diffraction patterns, the patent organizes the complexity into manageable, characterizable units that can be individually evaluated for therapeutic potential
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively inhibit IRAK4, providing a promising therapeutic approach for treating inflammatory and fibrotic diseases by modulating the associated signaling pathways.
Implementation Method 1
salts and solid forms of a compound that are inhibitors of the kinase IRAK4
Implementation Method 2
characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 7.5, 12.3, and 7.2°2θ as determined on a diffractometer using Cu-Kα radiation
Data Source
AI summary
The present disclosure relates to salts and solid forms of a compound that are inhibitors of the kinase IRAK4 and their uses as therapeutic agents for treating diseases, disorders, or conditions modulated by IRAK4, such as inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), psoriasis, or rheumatoid arthritis.